Suppr超能文献

低ABO血型凝集素效价的ABO血型不相容肾移植中的脱敏治疗

Desensitization in ABO-Incompatible Kidney Transplantation With Low ABO Iso-Agglutinin Titers.

作者信息

Gelpi R, Cid J, Lozano M, Revuelta I, Sanchez-Escuredo A, Blasco M, de Souza E, Esforzado N, Torregrosa J V, Cofán F, Ricart M J, Campistol J M, Oppenheimer F, Diekmann F

机构信息

Department of Nephrology and Renal Transplantation, Hospital Clinic, Barcelona, Catalonia, Spain.

Apheresis Unit, Department of Hemotherapy and Hemostasis, Hospital Clinic, Barcelona, Catalonia, Spain.

出版信息

Transplant Proc. 2015 Oct;47(8):2340-3. doi: 10.1016/j.transproceed.2015.08.021.

Abstract

BACKGROUND

In ABO-incompatible (ABOi) kidney transplantation (KT) with low iso-agglutinin (IG) titers (IGT), standard pre-conditioning treatment might be excessive. To try to answer this question, we evaluated the pre-conditioning requirements of a group of ABOi KT with low ABO IGT in our center. Our main objective was to assess desensitization requirements for ABOi KT with low IGT (<16) at Hospital Clinic of Barcelona from 2006 to 2014.

METHODS

A retrospective study of desensitization (rituximab and plasma exchange [PE]) requirements for ABOi KT with IGT <16 was conducted.

RESULTS

One and 5 years after KT, patient survival was 100%. Renal graft survival was 90% at 1 and 5 years after KT. Mean PE performed before KT was 1.7 (standard deviation [SD], 1.703); 50% of the patients did not receive PE after transplantation, 30% received 2 sessions of PE, and 20% received only 1. The average is 0.8 (SD, 0.91).Follow-up IG determinations remained with low titers (≤8/8). No rebounds of titers were observed during the first 4 to 6 months after transplantation.

CONCLUSIONS

Recipients with IGT ≤8 required none or only 1 PE session to reach acceptable titers (titers ≤4) to perform ABOi KT safely. This information is useful to assess the possibility of a minimized desensitization protocol in ABOi KT donors with low titers of IG to reduce adverse effects, reduce cost, and simplify pre-transplant logistics.

摘要

背景

在低同种凝集素(IG)滴度(IGT)的ABO血型不相容(ABOi)肾移植(KT)中,标准预处理可能过度。为回答这个问题,我们评估了本中心一组低ABO IGT的ABOi KT的预处理要求。我们的主要目的是评估2006年至2014年巴塞罗那临床医院低IGT(<16)的ABOi KT的脱敏要求。

方法

对IGT <16的ABOi KT的脱敏(利妥昔单抗和血浆置换[PE])要求进行回顾性研究。

结果

KT后1年和5年,患者生存率为100%。KT后1年和5年肾移植存活率为90%。KT前平均进行PE 1.7次(标准差[SD],1.703);50%的患者移植后未接受PE,30%接受2次PE,20%仅接受1次。平均值为0.8(SD,0.91)。随访IG测定仍为低滴度(≤8/8)。移植后前4至6个月未观察到滴度反弹。

结论

IGT≤8的受者无需或仅需进行1次PE即可达到可接受的滴度(滴度≤4)以安全进行ABOi KT。该信息有助于评估在低IG滴度ABOi KT供者中采用最小化脱敏方案的可能性,以减少不良反应、降低成本并简化移植前后勤工作。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验